http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
프로토 타입 조직등가비례계수기의 중입자가속기연구소의 135 MeV/u 탄소 이온에 대한 선형에너지 스펙트럼 측정
남욱원 ( Uk Won Nam ),이재진 ( Jae Jin Lee ),표정현 ( Jeong Hyun Pyo ),박원기 ( Won Kee Park ),문봉곤 ( Bong Kon Moon ),임창휘 ( Chang Hwy Lim2,),문명국 ( Myung Kook Moon ),하시시키다무라 ( Hisashi Kitamure ),신고고바야시 ( Shingo Kob 한국센서학회 2014 센서학회지 Vol.23 No.3
TEPC (Tissue Equivalent Proportional Counter) was usually used for high LET radiation dosimetry. We developed a prototype TEPC for micro-dosimetry in the range of 0.2~300 keV/μm. And, the simulated site diameter of the TEPC is 2 μm, of similar size to a cell nucleus. For purposes of characterization the response for high LET radiation of the TEPC has been investigated under 135MeV/u Carbon ions in HIMAC (Heavy Ion Medical Accelerator). We determined the gas multiplication factor and measured the lineal energy spectrum [yd(y)] of 135 MeV/u Carbon ions. The value of the gas multiplication factor was 315 at 700 V bias voltage. As a result of the experiment, we could more understand the performance of the TEPC for high LET (Linear Energy Transfer) radiation. And the procedure of high LET radiation dosimetry using TEPC is established.
A patient of congenitally corrected transposition of the great arteries as a kidney donor
( Jeong Uk Lim ),( Youn Hee Lee ) 대한내과학회 2013 대한내과학회 추계학술발표논문집 Vol.2013 No.1
Herein we present an unusual case of congenitally corrected transposition of great arteries(ccTGA) patient who has undergone successful nephrectomy for purpose of donating kidney to his distant cousin. A 48-yr-old man came to our hospital to donate his kidney and received preop evaluation. Echocardiography revealed corrected TGA, with aorta arising from morphologic RV and pulmonary artery arising from the morphologic LV, and morphologic RV`s ejection fraction checked 42%. Electrocardiography showed finding of complete AV block. After consulting with cardiology department, patient has undergone a nephrectomy. No complication has occurred during general anesthesia and postoperative care. An abnormal conduction system is common in ccTGA patients. If the patient with AV discordance and narrow-complex complete AV block has an adequate heart rate, insertion of the pacemaker is not obligatory. Our patient`s average heart rate was around 53 beats per minute, and series of electrocardiography showed finding of complete AV block with narrow QRS shape. No definite indication for pacemaker insertion was present for our patient. So it was possible to proceed with nephrectomy without further cardiac procedures. This case showed that kidney donation is possible for patients of ccTGA and complete AV block, if patient does not have indication for pacemaker insertion.
( Jeong Uk Lim ),( Yong Hyun Kim ),( Chang Dong Yeo ),( Ju Sang Kim ),( Chan Kwon Park ),( Jin Woo Kim ),( Seung Joon Kim ),( Sang Haak Lee ),( Hye Seon Kang ) 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.0
Background In patients with non-small cell lung cancer (NSCLC), both chronic obstructive pulmonary disease (COPD) and systemic inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet- lymphocyte ratio (PLR), have significant association with prognosis. NLR and PLR also predict mortality in patients with COPD alone. A combination of the two parameters may be helpful in a more individualized approach for predicting prognosis in patients with NSCLC. Methods Medical records of patients with stage IIIB and IV NSCLC from January 2012 to January 2018 from seven university hospitals were reviewed. Patients were categorized into four subgroups based on pulmonary function test Results and cutoffs for NLR or PLR. Results A total of 277 patients were evaluated and categorized into non-COPD and COPD groups; 194 patients were in the non- COPD group and 83 patients were in the COPD group. The non-COPD group showed significantly longer overall survival (OS) compared with the COPD group (P=0.019). Median survival of the low PLR group and high PLR group were significantly different at 29.3 months (95%CI, 20.0-38.6 months) and 11.8 months, respectively (P < 0.001). PLR showed a significant negative linear correlation with FVC (absolute), FVC (%), DLCO (absolute value), and DLCO (%). In the multivariate analysis for OS, male sex, EGFR mutation wild-type, not receiving active anticancer treatment, and low hemoglobin showed significant association with shorter OS (HR 1.477 (1.016-2.148), P=0.041; HR 0.501 (0.338-0.740), P=0.001; HR 2.937 (1.497-5.762), P=0.002; and HR 0.846 (0.756-0.947), P=0.004, respectively). The high PLR, COPD sub-group showed significantly higher risk for mortality (HR 2.066 (1.175-3.633), P=0.012) compared with the low-PLR non-COPD group. Conclusion A combination of COPD status and PLR may be a cost-effective and readily available prognostic marker in patients with advanced NSCLC.
( Jeong Uk Lim ),( Hye Seon Kang ),( Ah Young Shin ),( Chang Dong Yeo ),( Chan Kwon Park ),( Sang Haak Lee ),( Seung Joon Kim ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Background Local treatment (LT) such as radiotherapy and metastasectomy on metastatic sites can improve outcomes in oligometastatic NSCLC patients. Patients with single extrathoracic metastatic lesion are more likely to benefit from local therapy. In this study, we evaluated the efficacy of LT in NSCLC patients with a single extrathoracic metastatic lesion. Methods Data were obtained from the Korean Association for Lung Cancer Registry (KALC-R), a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee. Results A total of 787 NSCLC patients with a single extrathoracic metastatic lesion were evaluated. Regarding the LT modality, 17 (2.2%) patients underwent metastasectomy and 297 (37.7%) underwent radiotherapy. In the multivariate analysis for overall survival (OS), age, female sex, poor performance score, squamous histologic subtype, LT, and initial treatment modality showed significant associations. Regarding LT, groups that underwent curative LT showed significantly associated with better OS compared to groups that did not undergo LT (P=0.011, HR 0.448, 95% CI: 0.242-0.829). In the multivariate analysis of patients who underwent LT, poor performance score, initial treatment modality, and T stage were independently associated with poor OS. Compared to the T1 stage, T3 stage showed an HR of 2.470 (95% CI: 1.309-4.663; P=0.005) and T4 stage showed an HR of 2.063 (95% CI: 1.093-3.904; P=0.026). Conclusion In NSCLC with a single extrathoracic metastatic lesion, LT, especially for curative purposes, has an independent association with improved OS. Moreover, among the patients who received LT, factors such as T stage, poor performance score, and initial treatment modality were significantly associated with OS.
( Jeong Uk Lim ),( Chang Dong Yeo ),( Sung Kyoung Kim ),( Chan Kwon Park ),( Tae Jung Kim ),( Ju Sang Kim ),( Yong Hyun Kim ),( Seung Joon Kim ),( Sang Haak Lee ),( Hyong Kyu Yoon ),( Young Kyoon Kim 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: EGFR, KRAS and ALK gene mutations are major gene mutations foundin NSCLC patients, however there are limited studies about association between COPD and gene mutation frequency in NSCLC patient. Aim of this study is to evaluate gene mutation frequency in COPD patients compared with non COPD patients and clinical correlation between gene mutation frequency and GOLD stages in COPD patients.Methods: A total of 501 consecutive patients with NSCLC were referred to four hospitals of Catholic University of Korea for non-sequential, simultaneous panel genotyping of EGFR, KRAS, and ALK between January 2011 and April 2013. We comparedthe EGFR, KRAS and ALK gene mutation frequency in COPD patients with non COPD patients. Among COPD patients, we also compared gene mutation frequencies by differentGOLD stages. Results: Results show mutation frequency of EGFR and ALK decreased and KRAS increased in COPD patients compared with non-COPD patients. In COPD patients, as GOLD stages elevated, EGFR and ALK mutation frequency decrease gradually and KRAS mutation frequency increase gradually.Conclusions: Results show mutation frequency of EGFR and ALK decreased and KRAS increased in COPD patients compared with non-COPD patients. In COPD patients, as GOLD stages elevated, EGFR and ALK mutation frequency decrease gradually and KRAS mutation frequency increase gradually.
( Jeong Uk Lim ),( In Sook Woo ),( Yun Hwa Jung ),( Jae Ho Byeon ),( Chan Kwon Park ),( Tae Jung Kim ),( Hyo Rim Kim ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Although erlotinib has been found to markedly improve progression free survival and quality of life, most patients who show an initial response eventually develop disease progression. Acquired resistance due to histologic transformation have been recognized as one of the resistance mechanisms. Methods: We present a 33 year old male lung cancer patient who showed acquired resistance to erlotinib after histologic transformation into LCNEC with literature review. Results: A 33-year-old male was admitted to our institution for headache and diplopia.Brain MRI revealed multiple metastatic masses in the brain. A left frontal craniotomy was performed to remove the mass and after pathologic evaluation, he was diagnosed with metastatic lung adenocarcinoma harboring a deletion in exon19 of EGFR gene. He underwent cyberknife surgery followed by two cycles of pemetrexed-cisplatin as fi rst line chemotherapy. However, follow up CT showed progressive disease. Second line treatment with erlotinib for two months showed a partial response at the lung nodules, mediastinal lymph nodes and kidney masses. After 10 months of treatment with erlotinib, the right lower paratracheal lymph node increased in size from 1 to 3 cm. A rebiopsy of the right paratracheal lymph node by mediastinoscopy showedtwo different types of cells: adenocarcinoma cells, as shown on initial pathology; and LCNEC cells, comprising 50% of the microscopic fi eld. The EGFR gene in the second biopsy specimen was not analyzed due to patient refusal. Despite receiving three cycles of etoposide-cisplatin (EP) chemotherapy, along with maintenance erlotinib to prevent disease fi are up from erlotinib discontinuation, the disease progressed Conclusions: we describe a patient with metastatic lung adenocarcinoma who experienced a histologic transformation to combined LCNEC and adenocarcinoma of the lung during treatment with erlotinib.
Lim Jeong Uk 대한결핵및호흡기학회 2023 Tuberculosis and Respiratory Diseases Vol.86 No.1
A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), the landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained.